GN-HEARING
18.8.2020 09:02:06 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today unveils ReSound ONETM , a revolutionary new hearing aid* that solves one of the most enduring challenges for people with hearing loss. This unique solution places an additional microphone inside the ear canal, for the first time, allowing people relying on hearing aids to experience the world with their own ears while preserving the comfort of an open-fit device. Now every user can enjoy the benefits of superior sound quality and hear conversations better in noisy environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005077/en/
With its Organic Hearing philosophy, GN has always taken its design inspiration from how humans hear naturally and seeks to mimic this within its technology as closely as possible. Following this approach, ReSound ONE uniquely adapts to the needs and lifestyle of every individual rather than the other way around.
The outer ear (pinna) is designed by nature to work like an acoustic antenna. It helps the brain localize and tune in to a particular sound, for example when listening to a specific voice in a crowded café. However, the most popular styles of hearing aids (Receiver-In-Ear and Behind-The-Ear models) capture sound from microphones that sit behind the ear and then approximate the effect of the pinna. The result is an averaged and incomplete reproduction of sound, making it hard for the brain to achieve its natural localization and noise-cancelling function. In fact, of the 79 million people who wear hearing aids globally,1 93% report having trouble hearing in noisy environments and 55% get confused about where sounds come from.2
ReSound ONE is the world’s first full-featured* hearing aid with a Microphone & Receiver-In-Ear design (M&RIE) that uses the unique shape of every individual’s ear to collect sound. This remarkable innovation has been achieved with a radical new receiver system combined with all-new Digital Feedback Suppression (DFS Ultra III), enabled by GN’s new and most powerful sound-processing chipset ever. By picking up sound directly inside the ear, ReSound ONE gives the brain everything it needs to tune in to individual voices, as well as significantly reducing background noise. Clinical studies show that all hearing aid users benefit from listening to sounds collected with their own ears, with 90% of users preferring the sound quality of ReSound ONE with M&RIE instead of only the microphone behind the ear.3,4
GN Hearing CEO and President, Gitte Aabo explains, “I am very proud that, once again, GN is first in the industry with ground-breaking innovation that will make a genuine difference in how people experience conversations and sounds around them. Placing a microphone into the ear with an open-fit hearing aid is something the industry has battled for many years to achieve. This technology will allow people with hearing loss to feel that they are literally getting their own hearing back and hearing the way nature intended. ReSound ONE will boost the communication, relationships, and confidence of every individual.”
Additionally, ReSound ONE incorporates new All Access Directionality and the user-activated Ultra Focus settings. These enhanced operating modes significantly improve speech recognition while preserving spatial perception in complex sound and noise situations. ReSound ONE includes unmatched rechargeability and extensive connectivity options to both iOS and Android™ smartphones for streaming and hearing aid control.
ReSound ONE is available from August 27, 2020 in rechargeable and non-rechargeable models. This technology is also available in new Beltone Imagine hearing aids.
For further information, visit the ReSound Newsroom and read more about the Organic Hearing philosophy.
Learn more about GN’s 2020 and beyond strategy with focus on individualized customer experiences.
- ENDS –
NOTES TO EDITORS
About ReSound
ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The introduction of this new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn , Facebook and Twitter .
*ReSound ONE introduces the world’s first full-featured hearing aid with M&RIE for a truly individualized, more complete sound experience. Full-featured means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.
© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
References
- World Health Organization (2020) Deafness and hearing loss. Factsheet. https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss . Accessed: July, 2020
- MarkeTrak 2019
- Jespersen et al (2020): M&RIE receiver preferred for sound quality and localization. ReSound white paper
- Groth J. (2020). An innovative RIE with microphone in the ear lets users “hear with their own ears”. ReSound white paper
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
